• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Alerts
CMECNE

Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Describe the evaluation of women presenting with symptoms that may be suggestive of mood disorder
2. Apply a depression screening tool such as the PHQ-9 Questionnaire in your practice

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Sep 25 2018 through Jan 25 2023, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Designated for 0.1 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Read Disclaimer & Fine Print

SUMMARY: 

Perimenopause, or transitional menopause, is defined as the early transition stages into menopause as well as the early post-menopause stage. It is a particularly vulnerable time for depressive symptoms and major depressive episodes in women.  The following are the guidelines on evaluation and management of perimenopausal depression developed by NAMS in collaboration with the National Network of Depression Centers Women and Mood Disorders Task Group expert panel. The guidelines address an approach to depressive symptoms and depressive disorders in midlife women.  

KEY POINTS:

Epidemiology and Risk Factors  

Epidemiology 

  • Risk increased for both depressive symptoms and major depressive episodes (MDE) during the perimenopause  
  • Risk for depressive symptoms is elevated in the perimenopause even without previous history  

Risk Factors for Depressive Symptoms  

  • Prior Major Depressive Disorder (MDD) 
  • Reproductive-related mood disturbance  
    • Postpartum and/or premenstrual depressive symptoms 
  • Sociodemographic factors including  
    • Younger age | Black race | Financial difficulties 
  • Psychosocial factors   
    • Adverse life events | Low social support 
  • Anxiety symptoms 
  • Common midlife stressors  
  • Menopausal symptoms 
    • VMS | Sleep disturbance  

Risk factors for MDD 

  • Mental health factors  
    • Prior MDD | Current use of antidepressants | Anxiety | Premenstrual depressive symptoms  
    • Sociodemographic factors (e.g., black race, high BMI, younger age)  
    • Psychosocial factors (e.g., upsetting life events and social isolation)  
    • Menopausal symptoms (sleep disturbance) 
  • Limited and/or inconclusive data  
    • Data suggests increased risk following hysterectomy with and without oophorectomy | Premature Ovarian Failure 
    • Literature review can be found in the full open access guideline paper (‘Primary Sources – Learn More’ below)  

Assessment and Diagnosis 

The guidelines state  

Depression during midlife presents with classic depressive symptoms, commonly in combination with menopause specific symptoms (ie, VMS, sleep disturbance) and psychosocial challenges. 

Diagnostic Criteria (DSM-5)  

MDD aka ‘Depression’ 

  • Discrete episodes of Major Depressive Episodes (MDE) 
    • ≥2 weeks’ duration (most longer) with significant changes in at least 5 of the following  
    • Altered Affect (depressed mood) | Cognition | Impaired concentration  | Diminished interest in pleasure | Weight and appetite changes | Sleep disturbance | Restless or slowed down | Fatigue | Feeling worthless or guilty | Thoughts of death or suicidal ideation with or without a plan  
    • MDE must include either depressed mood or loss of interest in pleasure 
    • Symptoms are present every day throughout the episode  
  • Significant effect on daily living, including social and occupational interactions  
  • No other explanation for the situation (e.g., medical disorder, such as a stroke)  

Clinical assessment  

  • Determine the specific menopause stage 
  • Assess psychosocial risk factors and overlapping menopause and psychiatric symptoms 
  • Identify women with  
    • Past major depressive disorder  
    • Severe depressive symptoms  
    • Suicidal ideation  
  • Differential during menopausal transition includes  
    • MDD | Subsyndromal depression | Adjustment disorder | Psychological distress | Bereavement | Bipolar Depression | General medical causes of depression 
    • Most women who experience a MDE are likely experiencing a recurrence  

Note: Refer women with past MDEs and severe depressive symptoms for as professional evaluation for the presence of mood disorder 

Screening Tools 

  • There is no specific ‘menopause’ mood disorder screening tool  
  • There are a variety of validated general screening tools that can be used including  
    • PHQ-9 (see ‘Learn More – Primary Sources’ below)
  • To clarify contribution of menopause-related symptoms, consider the use of the following Quality of Life (QoL) tools  (see ‘Learn More – Primary Sources’ below)
    • Menopause Rating Scale (MRS) | Menopause-Specific Quality-of-Life Scale (MENQOL) | Greene Climacteric Scale | Utian Quality-of-Life Scale 

Treatment 

  • First line of treatment should include demonstrated therapeutic options for depression  
    • Antidepressants 
    • CBT  
    • Psychotherapy 

Antidepressants 

  • Desvenlafaxine has been studied in large RCTs that included postmenopausal depressed women and has proved to be effective 
  • Other SSRIs and SNRIs at regular doses are well tolerated and effective 
    • Citalopram | Duloxetine | Escitalopram | Fluoxetine | Sertraline | Venlafaxine 
    • Those used by patients successfully in past MDEs should be considered for first line treatment 
    • Some SSRIs and NSRIs also help with menopausal symptoms including hot flashes, night sweats and sleep disturbances 
  • Pay special attention to potential adverse effects in patients given the unique challenges of this population including  
    • Sexual dysfunction 
    • Weight changes  
    • Interactions with other medications 

Estrogen-Based Therapies (ET) 

  • Estrogen is not FDA approved to treat mood disturbance 
  • Consideration might be given for ET use specifically during the perimenopause 
    • Some evidence that ET has antidepressant effects in perimenopause but not postmenopause 
    • ET may enhance mood and well-being in non-depressed perimenopausal women  

ET used together to enhance antidepressants should be used with caution  

  • ‘Preferably’ in women who require treatment for vasomotor symptoms 
  • Data on combined estrogen and progestogen are sparse and inconclusive 
  • Hormonal contraceptives  
    • Used continuously, have shown some benefits for mood regulation for women approaching menopause 

Note: Studies on hormone therapy (HT) and depression focused on unopposed estrogen. Combined HT is not well studied and data is inconclusive  

Alternative (supplements and non-traditional) approaches 

  • Evidence is insufficient for recommending use at this time  

Exercise 

  • It is reasonable to recommend exercise in peri- and postmenopausal women with depression when used in combination with recommended psychotherapies and pharmacotherapies 

Learn More – Primary Sources:

NAMS: Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations

DSM-5 and mental disorders in older individuals: an overview 

Major depression

Diagnostic and Statistical Manual of Mental Disorders (DSM–5) 

PHQ-9 Screening Tool (University of Michigan)

Menopause Rating Scale (MRS): A methodological review  

NAMS: Utian Quality of Life Scale

Take a post-test and get CME credits

TAKE THE POST TEST

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite

< Previous
All Alerts Posts
Next >

Related ObG Topics:

North American Menopause Society: Hormone Therapy Statement
Does Hormone Treatment Prevent Depression in Menopausal Women?
Insomnia in Menopause: How do Treatments Compare?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site